The COVID-19 pandemic contributed to significant disruptions in breast, colorectal and cervical cancer screenings among federally qualified health systems spanning 15 states across the U.S.
Researchers at the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective.
In a sign that pain management for patients dying of cancer is worsening, a new study by Dana-Farber Cancer Institute investigators has found a sharp decline in opioid access among these patients over a recent 10-year period, even as many more of them turned to hospital emergency rooms for pain treatment.
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.
A new study led by scientists from the International Agency for Research on Cancer shows that an estimated 741,000 new cases of cancer in 2020 were associated with alcohol consumption globally.
A new prognostic tool helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.
A cancer survivorship study is focusing on Kentucky cancer survivors with any type of cancer, and comparing the results within the state.
St. Jude Children’s Research Hospital scientists have created a registry, Molecular Analysis of Childhood MELanocytic Tumors (MACMEL), to better understand pediatric melanoma.
Findings from the health outcomes group at Fred Hutchinson Cancer Research Center show that more Medicaid patients with cancer died at home without hospice care during the COVID-19 pandemic.
A study led by researchers at NYU Langone Health and Perlmutter Cancer Center shows that Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to get them than non-Black men.
